



Trabajo Original

Obesidad y síndrome metabólico

Predictive value of the Chinese Visceral Adiposity Index for disease activity and vedolizumab response in ulcerative colitis

Valor predictivo del índice de grasa visceral chino sobre la actividad de enfermedad y la respuesta al vedolizumab en la colitis ulcerosa

Yibing Hu, Jiaojiao Wei, Minli Hu, Yuan Chen, Yafang Li, Chong Lu, Xiao-Yun Yang, Jin Ding, Qunying Wang

Department of Gastroenterology. Affiliated Jinhua Hospital. Zhejiang University School of Medicine. Jinhua, Zhejiang. People's Republic of China

Abstract

Objective: ulcerative colitis (UC) is characterized by chronic nonspecific inflammation of the intestinal tract. The identification of non-invasive biomarkers that can reflect intestinal inflammation and predict therapeutic response is vital. This study aimed to assess the predictive value of the Chinese Visceral Adiposity Index (CVAI) for the assessment of both disease activity and response to vedolizumab therapy.

Methods: this retrospective study analyzed clinical data from patients with UC between January 2021 and December 2023. Healthy individuals were recruited as controls. Disease activity was evaluated using the modified Mayo score, while clinical response was assessed using patient-reported outcomes (PRO2). Mayo Endoscopic Score (MES) was used for the grading of mucosal lesions. Receiver operating characteristic (ROC) curves were used to assess the ability of various indices to differentiate between patients with UC and healthy controls.

Results: patients with UC ($n = 82$) had significantly higher CVAIs compared to healthy controls ($n = 72$) (36.34 ± 19.82 vs. 55.93 ± 25.14 , $p < 0.001$). ROC analysis indicated that CVAI was the most effective predictive factor in distinguishing between patients with UC and healthy controls, with the highest area under the curve ($AUC = 0.720$). The CVAI was significantly correlated with clinical activity and endoscopic scores in patients with UC, while patients who responded to vedolizumab had lower pre-treatment CVAIs compared to non-responders (54.14 ± 15.45 vs. 72.84 ± 21.44 , $p = 0.002$). A low pre-treatment CVAI score was also effective in predicting the response to vedolizumab ($AUC = 0.789$).

Conclusion: the CVAI may be a valuable marker for assessing disease activity in UC and has the potential to predict the response to vedolizumab therapy.

Keywords:

Chinese Visceral Adiposity Index. Ulcerative colitis. Vedolizumab.

Received: 08/09/2024 • Accepted: 15/06/2025

Authors' contributions: Planning and conducting the study: Yibing Hu, Jiaojiao Wei, Yafang Li; data collection: Yibing Hu, Chong Lu, Minli Hu, Yuan Chen; data interpretation: Xiao-Yun Yang, Jin Ding, Qunying Wang; drafting of the manuscript: Yibing Hu, Qunying Wang. Yibing Hu and Jiaojiao Wei contributed equally to this work.

Data availability statement: The datasets generated and analyzed in the study are available from the corresponding author on reasonable request.

Conflict of interest: The authors declare no conflict of interest.

Artificial intelligence: The authors declare not to have used artificial intelligence (AI) or any AI-assisted technologies in the elaboration of the article.

Hu Y, Wei J, Hu M, Chen Y, Li Y, Lu C, Yang XY, Ding J, Wang Q. Predictive value of the Chinese Visceral Adiposity Index for disease activity and vedolizumab response in ulcerative colitis. *Nutr Hosp* 2025;42(5):916-923

DOI: <http://dx.doi.org/10.20960/nh.05519>

Correspondence:

Qunying Wang, Department of Gastroenterology. Affiliated Jinhua Hospital. Zhejiang University School of Medicine. No. 365 Renming East Road. Jinhua, Zhejiang. People's Republic of China
e-mail: qunyingwang2018@163.com

Resumen

Objetivo: la colitis ulcerosa (CU) es una enfermedad inflamatoria intestinal crónica de etiología inespecífica. La identificación de biomarcadores no invasivos que reflejen la actividad inflamatoria y predigan la respuesta terapéutica representa una necesidad clínica prioritaria. Este estudio tuvo como objetivo evaluar la utilidad del índice de grasa visceral de China (*China Visceral Adiposity Index*, CVAI) para determinar la actividad clínico-endoscópica de la CU y predecir la respuesta al tratamiento con vedolizumab.

Métodos: estudio retrospectivo que incluyó pacientes con CU (enero 2021-diciembre 2023) y controles sanos emparejados. La actividad clínica se evaluó mediante la puntuación Mayo modificada, y la respuesta terapéutica mediante el índice PRO2. La gravedad endoscópica se clasificó según la puntuación Mayo endoscópica (*Mayo Endoscopic Score*, MES). Se realizaron análisis ROC para comparar la capacidad discriminativa del CVAI entre grupos.

Resultados: los pacientes con CU ($n = 82$) presentaron valores de CVAI significativamente superiores a los controles ($n = 72$) ($55,93 \pm 25,14$ vs. $36,34 \pm 19,82$; $p < 0,001$). El análisis ROC demostró que el CVAI mostró la mayor capacidad discriminativa ($AUC = 0,720$; IC 95 %: 0,65-0,79). Se observó una correlación positiva entre el CVAI y las puntuaciones clínicas ($r = 0,58$; $p < 0,01$) y endoscópicas ($r = 0,62$; $p < 0,01$). Los respondedores a vedolizumab presentaron valores basales de CVAI significativamente inferiores a los no respondedores ($54,14 \pm 15,45$ vs. $72,84 \pm 21,44$; $p = 0,002$), mostrando el CVAI una capacidad predictiva moderada ($AUC = 0,789$; IC 95 %: 0,68-0,89).

Conclusión: el CVAI constituye un biomarcador prometedor para evaluar la actividad clínico-endoscópica en CU y podría predecir la respuesta terapéutica a vedolizumab, ofreciendo una herramienta accesible para la toma de decisiones clínicas.

Palabras clave:

Índice de grasa visceral de China. Colitis ulcerosa. Vedolizumab.

INTRODUCTION

Ulcerative colitis (UC) is a nonspecific inflammatory bowel disease primarily affecting the rectum and colon, with an unclear pathogenesis (1). It is a significant health burden, and the global incidence of UC has increased in recent years, particularly in Asian countries, including China (2,3). Patients with UC often experience recurrent abdominal pain and bloody stools with mucus associated with disease activity. However, an absence of symptoms does not necessarily indicate complete remission, necessitating methods for monitoring disease activity at the onset of symptoms and during treatment (4). Biologics are among the key therapies used for UC. The United States Food and Drug Administration (FDA) and China's National Medical Products Administration approved the use of vedolizumab for UC treatment in 2014 and 2020, respectively. Numerous studies have confirmed the efficacy of vedolizumab in inducing and maintaining clinical remission and mucosal healing in UC, although not all patients respond to this treatment (5,6). Thus, given the high cost and potential adverse effects associated with vedolizumab, there is an urgent need to predict and identify patients who are likely to respond to this treatment before initiating treatment as this would reduce the economic burden on patients and optimize the therapeutic efficacy of vedolizumab.

The deposition of adipose tissue, particularly of visceral fat which is known to have a pro-inflammatory role, has been found to be involved in both the pathogenesis and progression of UC. Several studies have demonstrated that visceral adiposity can not only predict the onset of inflammatory bowel disease but is also closely associated with clinical and endoscopic remission in patients undergoing biological therapy (7,8). Visceral fat tissue is traditionally assessed using computed tomography (CT) and magnetic resonance imaging (MRI) (9). However, these imaging techniques are expensive, with long waiting times for appointments, and CT exposes patients to radiation. While endoscopy can reflect disease activity, it is an invasive procedure requiring time-consuming bowel preparation, and is thus impractical for

frequent monitoring. Similarly, the use of fecal calprotectin, despite being a non-invasive marker for assessing disease activity, is often associated with difficulties in the prompt collection of samples by patients for analysis. There is thus a long-standing need for a method that is non-invasive, permits repeated assessments, and can monitor disease activity effectively.

Currently, several indicators are used to reflect adiposity deposition. These include body mass index (BMI), waist circumference, visceral adiposity index (VAI), lipid accumulation product index (LAP), and the body roundness index (BRI) (10-13). However, these indices have limitations in that they either do not provide an accurate reflection of visceral adiposity deposition or may not represent the true characteristics of the Chinese population. Xie et al. (14) reported the use of the Chinese visceral adiposity index (CVAI) to diagnose visceral adiposity deposition in the Chinese population, and its predictive ability was validated in a cross-sectional study involving over 450 participants (14). This index is also closely associated with several obesity-related diseases, including diabetes and hypertension, and it is known that obesity can influence the progression of inflammatory bowel disease (IBD) and the response to treatment (15,16).

The CVAI is calculated using age, BMI, waist circumference, and the levels of triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C). These measurements are easy to obtain, can be measured repeatedly, and are non-invasive. This study aimed to evaluate the relationship between the CVAI and disease activity in UC, as well as explore its value in predicting the response to vedolizumab treatment in UC.

MATERIALS AND METHODS

STUDY POPULATION

This retrospective study involved 84 patients with UC who were treated at the IBD Center of Jinhua Hospital, affiliated with Zhejiang University School of Medicine, between January

2021 and December 2023. All patients were aged 18 years or older. The exclusion criteria included the presence of malignant tumors, severe cardiac, pulmonary, hepatic, or renal insufficiency, and recent use of medications that could affect triglyceride or HDL levels. To minimize the influence of steroids on vedolizumab treatment and the predictive value of CVAI, vedolizumab treatment was initiated two weeks after the last steroid treatment. A control group of 72 age- and sex-matched individuals who underwent routine examinations at the hospital during the same period was also included. All patients provided written informed consent. The study was approved by the Ethics Committee of Jinhua Hospital (Approval No. 2024-29).

SCORING OF DISEASE ACTIVITY

The extent of UC was categorized as follows: 1) E1, rectal type; 2) E2, left-sided colitis (with involvement up to the splenic flexure); 3) E3, extensive colitis (with involvement beyond the splenic flexure or including the entire colon). Disease activity was assessed using the modified Mayo score. Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1 , while an individual subscore > 1 indicated non-remission, and a Mayo score > 2 represented active disease (with 3-5 points indicating mild activity, 6-10 points indicating moderate activity, and 11-12 points indicating severe activity). During follow-up, clinical response was defined as a $\geq 50\%$ reduction in patient-reported outcomes (PRO2). The severity of mucosal disease was scored using the Mayo Endoscopic Score (MES) system as follows: 1) 0 points, normal mucosa or no active lesions; 2) 1 point, mucosal erythema, reduced vascular pattern, and mild friability; 3) 2 points, pronounced mucosal erythema, lack of vascular pattern, friability, and mucosal erosion; 4) 3 points, spontaneous bleeding and ulcer formation.

CLINICAL EVALUATION AND LABORATORY TESTS

Data on demographics, laboratory test results, and other relevant information were collected from the electronic medical records system. During the induction phase, 300 mg of vedolizumab was administered intravenously at weeks 0, 2, and 6, while, during the maintenance phase, 300 mg was given intravenously every 8 weeks. Blood tests, including routine blood tests, C-reactive protein (CRP), liver and renal function tests, erythrocyte sedimentation rate (ESR), and lipid profiles, were performed before each infusion. Effectiveness was assessed 12-14 weeks after the initial vedolizumab infusion and was classified into clinical response and primary non-response based on the PRO2 score. Additionally, the CVAI index was calculated before and after treatment. The CVAI was computed as follows: For males: $-267.93 + 0.68 \times \text{age} + 0.03 \times \text{BMI} + 4 \times \text{WC (cm)} + 22 \times \text{Log10 TG (mmol/L)} - 16.32 \times \text{HDL-C (mmol/L)}$. For females: $-187.32 + 1.71 \times \text{age} + 4.32 \times \text{BMI} + 1.12 \times \text{WC (cm)} + 39.76 \times \text{Log10 TG (mmol/L)} - 11.66 \times \text{HDL-C (mmol/L)}$.

STATISTICAL METHODS

Normally distributed continuous variables are expressed as mean $\pm$ standard deviation, with comparisons between groups conducted using t-tests. Non-normally distributed continuous variables are expressed as median and interquartile range, with group comparisons performed using the Mann-Whitney U-test. Categorical data are expressed as percentages, and were compared using chi-square or Fisher's exact tests. For comparisons among the mild, moderate, and severe UC groups, the Kruskal-Wallis test was used, with pairwise comparisons conducted using Dunn's test. The ability of the CVAI to differentiate between different groups was assessed using receiver operating characteristic (ROC) curves. The correlation between the CVAI and disease activity was evaluated using Pearson's correlation coefficient. A p -value of less than 0.05 was considered statistically significant. Statistical analyses were performed using the Prism, version 9.0 software.

RESULTS

BASELINE CLINICAL CHARACTERISTICS

Table I presents the baseline clinical data for healthy controls and patients with UC. There were no significant differences in hemoglobin and albumin levels between the two groups. However, patients with UC had significantly higher TG levels, WC, and CVAI compared to the healthy controls (TG: 0.98 ± 0.33 vs. 1.25 ± 0.40 , $p < 0.001$; WC: 71.56 ± 5.48 vs. 75.21 ± 3.58 , $p < 0.001$; CVAI: 36.34 ± 19.82 vs. 55.93 ± 25.14 , $p < 0.001$). Conversely, HDL-C levels were lower in patients with UC than in healthy controls (1.18 ± 0.27 vs. 0.98 ± 0.29 , $p < 0.001$). Notably, the CVAI index in patients with UC was 1.5 times higher than that in the healthy population. The ROC curve analysis revealed that CVAI had the highest area under the curve (AUC = 0.720) value among the four metrics, indicating superior predictive ability compared to TG (AUC = 0.693), WC (AUC = 0.702), and HDL-C (AUC = 0.707) (Fig. 1). Thus, the CVAI may be a practical clinical marker for UC.

CLINICAL AND ENDOSCOPIC ACTIVITY OF UC AS REFLECTED BY THE CHINESE VISCERAL ADIPOSITY INDEX

A modified Mayo score was used to classify UC clinical activity into remission and active phases. It was observed that the CVAI index was significantly elevated in patients during the active phase (33.64 ± 21.99 vs. 60.27 ± 22.87 , $p < 0.001$) (Fig. 2A). The ROC curve analysis confirmed that the CVAI index was effective as an indicator to differentiate between the remission and active phases of UC, with an AUC of 0.809, a cut-off value of 45.87, a sensitivity of 0.857, a specificity of 0.764, and a Youden index of 0.622 (Fig. 2B). After the classification of active UC into mild, moderate, and severe stages, it was found that the CVAI index values were significantly higher in moderate and severe UC compared to mild UC ($41.27 \pm$

Table 1. Baseline clinical characteristics of patients with UC and healthy controls

Clinical parameters	Healthy controls (n = 72)	UC (n = 84)	p-value
Age, year	42.75 ± 12.96	46.89 ± 14.82	0.07
Female, n (%)	42 (58.33 %)	47 (57.31 %)	0.90
BMI, kg/m ²	21.68 ± 4.01	22.61 ± 3.12	0.11
Disease extent, n (%)			
E1	-	6 (7.32 %)	
E2	-	37 (45.12 %)	
E3	-	39 (47.56 %)	
Disease activity, n (%)			
Remission	-	14 (17.07 %)	
Mild	-	17 (20.73 %)	
Moderate	-	40 (48.78 %)	
Severe	-	11 (13.42 %)	
Laboratory tests			
Hemoglobin, g/L	126.03 ± 21.14	130.84 ± 18.33	0.13
Albumin, g/L	39.30 ± 6.47	38.56 ± 5.26	0.47
CRP, mg/L	-	8.84 ± 19.73	
ESR, mm/h	-	18.91 ± 19.48	
TG, mmol/L	0.98 ± 0.33	1.25 ± 0.40	< 0.001
HDL-C, mmol/L	1.18 ± 0.27	0.98 ± 0.29	< 0.001
Adiposity indexes			
WC (cm)	71.56 ± 5.48	75.21 ± 3.58	< 0.001
CVAI	36.34 ± 19.82	55.93 ± 25.14	< 0.001

BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; TG: triglycerides; HDL-C: highdensity lipoprotein cholesterol; WC: waist circumference; CVAI: Chinese Visceral Adiposity Index.




Figure 1. Receiver operating characteristic curves for distinguishing patients with UC from healthy controls using measurements of triglyceride and high-density lipoprotein cholesterol levels, waist circumference, and the CVAI.




Figure 2. Correlation between the CVAI index and disease activity in patients with UC. A. Association of the CVAI index with disease activity, divided into remission and active disease according to the modified Mayo score. B. Receiver operating characteristic curve in which the CVAI index was used to distinguish between patients with UC in remission and those with active-phase UC. $p < 0.05$ was defined as statistically significant. *** $p < 0.001$.

15.64 vs. 57.19 ± 11.27 , $p < 0.001$; 41.27 ± 15.64 vs. 100.86 ± 12.43 , $p < 0.001$) (Fig. 3A). In addition, ROC curve analysis showed that the CVAI index could distinguish between mild and moderate-to-severe UC activity, with an AUC of 0.843, a cut-off value of 46.88, a sensitivity of 0.765, a specificity of 0.882, and a Youden index of 0.647 (Fig. 3B). These results indicate that the CVAI index can be used to monitor UC disease activity. Apart from symptom control, mucosal healing is also an important aspect of the treatment of UC. Mucosal activity was assessed using the MES and was found to be positively correlated with the CVAI index (Pearson's $r = 0.845$, $p < 0.001$) (Fig. 4). These data demonstrate that the CVAI index is an effective reflection of endoscopic activity in patients with UC and is especially useful in those who require frequent endoscopic examinations to evaluate mucosal healing.

PREDICTIVE VALUE OF THE CHINESE VISCERAL ADIPOSITY INDEX INDEX FOR RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH UC

A total of 51 patients with UC were treated with vedolizumab. According to the PRO2 assessment, 17 patients were found to be




Figure 3. Correlation between the CVAI index and disease severity in patients with UC. A. The CVAI index was associated with disease severity, classified as mild, moderate, and severe. B. Receiver operating characteristic curve in which the CVAI index was used to distinguish patients with mild and moderate to severe UC. $p < 0.05$ was defined as statistically significant. *** $p < 0.001$.




Figure 4. Correlation between the CVAI index and the Mayo Endoscopic Score (MES) in UC. $p < 0.05$ was defined as statistically significant.

non-responders, while 34 patients achieved a clinical response. Before each infusion of vedolizumab, patients underwent hematological tests, measurements of fecal calprotectin and WC,

and calculation of the CVAI index. It was found that patients who achieved a clinical response had a significantly lower CVAI index before treatment compared to the primary non-responders (54.14 ± 15.45 vs 72.84 ± 21.44 , $p = 0.002$) (Fig. 5A). The ROC curve analysis indicated that the CVAI index was an effective predictor of the response of patients with UC vedolizumab, with an AUC of 0.789, a cut-off value of 53.18, sensitivity of 0.853, specificity of 0.706, and Youden's index of 0.559 (Fig. 5B). During the 1-year follow-up period, responders to vedolizumab showed reduced CVAI indices (72.84 ± 21.44 vs. 50.07 ± 19.82 , $p < 0.001$) (Fig. 6A), in contrast to non-responders who exhibited no significant change in the CVAI index (54.14 ± 1 vs. 59.73 ± 19.70 , $p = 0.364$) (Fig. 6B).




Figure 5. The CVAI index predicts the response to vedolizumab in patients with UC during induction. A. Comparison of the CVAI index of patients with primary non-response and those with clinically responsive UC before treatment. B. Receiver operating characteristic curve analyzing the ability of the pre-treatment CVAI index value in distinguishing between primary nonresponse and clinical response. $p < 0.05$ was defined as statistically significant. * $p < 0.05$.

DISCUSSION

Many studies, including those on inflammatory bowel disease, have explored the use of simple tools, often based on routine laboratory tests or readily accessible measurements, to assess disease severity and long-term prognosis (17,18). Currently, the methods available for evaluating and monitoring UC remain




Figure 6. The CVAI index predicted the response of patients with UC to vedolizumab during follow-up. A. Comparison of the values of the CVAI index between the pre-treatment and follow-up periods in patients with UC who achieved clinical response to vedolizumab. B. Comparison of the values of the CVAI index in patients with UC who did not respond to vedolizumab before treatment and during follow-up. $p < 0.05$ was defined as statistically significant. *** $p < 0.001$.

somewhat limited. This study is the first to evaluate the relationship between the CVAI and UC activity, as well as the response to vedolizumab in patients with UC. It was found that CVAI scores were higher in patients with UC relative to healthy individuals. Further analysis using the modified Mayo score revealed a close relationship between the CVAI and UC activity. Furthermore, the MES results indicated a significant correlation between the CVAI and UC severity as assessed by endoscopy, suggesting that the CVAI represents an effective measure of endoscopic inflammatory activity in UC. Additionally, the study found that patients with UC who responded to vedolizumab had lower CVAI scores prior to treatment compared to non-responders. ROC curve analysis further confirmed that a low CVAI score is a good predictor of response to vedolizumab in patients with UC. It can thus be concluded that the CVAI may be a valuable and promising indicator for predicting both UC disease activity and response to vedolizumab.

The assessment of disease activity in patients with UC, particularly the degree of mucosal inflammation, is crucial for effective treatment. Accurate and objective evaluations, along with timely judgments, are necessary for the implementation of appropriate therapeutic strategies (19). Objective methods for assessment are essential and include endoscopic and imaging evaluations. Imaging methods, such as CT, MRI, and intestinal ultrasound, have limitations. Specifically, CT involves radiation exposure, MRI is relatively expensive, and intestinal ultrasound, while useful, is not universally available in all hospitals in China and its accuracy is dependent on the skill level of the operator. These methods are thus not suitable for frequent use (20-22). Although endoscopy is the gold standard for assessing and monitoring intestinal inflammation in patients with UC, it requires thorough bowel preparation and is an invasive procedure with associated risks such as perforation and bleeding, thus restricting its frequent use (23,24). The measurement of fecal calprotectin is a non-invasive and relatively inexpensive method for evaluating UC activity; however, the collection of samples is often inconvenient, and many patients have difficulty delivering samples promptly to

the hospital for testing (25). Therefore, the use of simple hematological indices or easily accessible testing tools for evaluating and monitoring UC activity is highly desirable and could improve patient compliance.

Many recent studies have shown that adipose tissue, particularly visceral adipose tissue, plays a role in the development and progression of IBD (26,27). However, another single-center cross-sectional study found no association between visceral adiposity and the extent of UC lesions (28). Visceral adiposity appears to be more closely related to IBD outcomes, while traditional measures, such as BMI and waist circumference, although indicative of obesity, do not effectively represent abdominal visceral adiposity. A recent retrospective study involving 100 UC patients demonstrated that patients with IBD and a high visceral adiposity index were more likely to experience adverse IBD-related events within a short period; however, similar associations were not found with BMI (29). Traditionally, assessments of visceral adiposity in patients with IBD have relied on CT, MRI, or biopsies, each of which has limitations and results that are highly dependent on the operator's experience.

The CVAI index is associated with various diseases, including metabolic-associated fatty liver disease, diabetes, and renal injury. A study by Li et al., which included 99,201 individuals enrolled between 2015 and 2017, utilized ROC curve analysis to demonstrate that the CVAI index was more effective in predicting the risk of early hypertension compared to other indices, such as BMI and WC (30). The CVAI index incorporates age, physical measurements (BMI and WC), and biochemical markers (TG and HDL-C). A study from Korea found that in individuals with abdominal obesity, a higher WC increased the likelihood of progression to Crohn's disease (CD), although this was not observed in patients with UC (31). Similar results were reported in American women, where a WC greater than 84 cm was associated with a 1.56-fold increased risk of progressing to CD compared to a WC value of less than 70 cm, whereas no such risk was noted for UC (32). However, a recent study has suggested that abdominal visceral

adiposity is as important for UC as for CD (33). It was previously thought that creeping abdominal fat might be a primary initiator of inflammatory factor production in patients with CD, although this study posits that creeping fat should be considered a result rather than a cause of intestinal inflammation, and is thus significant for both UC and CD. Several researchers have also observed a trend of decreasing WC with disease improvement during UC treatment, although changes in BMI and body weight were not noted, suggesting a possible link between WC and UC (34). These differing conclusions may be partly attributed to differences in study populations, as adiposity distribution can differ by region. Studies have reported that Asians might be more prone to the accumulation of visceral adiposity compared to Caucasians (35,36). Another factor could be variations in disease activity levels among study groups; most studies have included patients with UC who are in remission and have not analyzed the relationship between disease activity and visceral adiposity indices. The relationship may vary between mild and moderate to severe cases, and the present study provides further analysis in this regard. IBD is associated with an increased risk of coronary heart disease, with dyslipidemia being an independent risk factor. A study involving 701 patients with IBD found that compared to healthy controls, patients with IBD (including CD and UC) were more likely to exhibit elevated triglyceride levels, which are associated with IBD surgical events (37). Furthermore, Japanese researchers reported a positive correlation between complete mucosal healing in UC and HDL-C levels, observed in patients with UC not undergoing lipid-lowering treatment (37). This finding aligns with the conclusions of the present study. Therefore, the CVAI index, which includes these indicators, may be more suitable for assessing visceral adiposity levels in the Chinese population.

Vedolizumab is a recombinant humanized IgG monoclonal antibody that binds specifically to integrin $\alpha 4\beta 7$ on the surfaces of targeted memory T-lymphocytes. It inhibits the migration of lymphocytes to sites of inflammation in the gastrointestinal tract, thereby preventing intestinal inflammation. Numerous randomized controlled trials (RCTs) and real-world studies have demonstrated the efficacy of vedolizumab in treating UC. A study by Kim et al. reported a 68.0 % clinical response rate at 14 weeks when treating UC patients with vedolizumab, while a real-world study from China reported a response rate of 73.4 %. This indicates that nearly 30 % of patients may not achieve a clinical response at 14 weeks, representing the primary non-responders (38,39). The early identification of these patients would allow effective treatment adjustments, thus avoiding prolonged damage and helping to alleviate the economic burden. Several earlier studies have explored the relationship between abdominal visceral adiposity and biological therapy patients with IBD. Most of these studies suggested that the presence of abdominal visceral adiposity may influence the efficacy of anti-TNF therapy (33,40). However, there is limited information on the relationship between abdominal visceral adiposity and vedolizumab treatment. The present study found that the value of the CVAI index before treatment can predict whether patients with UC will respond to vedolizumab. Patients with lower CVAI indices may

exhibit a better clinical response to vedolizumab.

This study found several advantages in the utilization of the CVAI index. First, the CVAI index is easy to measure, requiring only routine hematological indicators and simple physical data, and is thus non-invasive. Second, the CVAI index can be measured repeatedly and offers objectivity without reliance on human factors. Third, the CVAI index holds potential value for assessing disease activity and treatment outcomes. However, there are limitations to this study. First, it was a single-center retrospective study, and thus prone to bias. Prospective longitudinal studies are needed to verify the current observations. Second, the sample size was relatively small, and some patients with incomplete data were not included. The absence of calprotectin data represents a limitation; this was caused primarily by the high cost of testing in China and the lack of available testing infrastructure at our institution during the study period. Future multicenter collaborations using standardized biomarker protocols may mitigate this issue. Third, there was a lack of long-term follow-up data.

CONCLUSION

In summary, this study demonstrates the potential of the CVAI index in evaluating disease activity and predicting treatment response to vedolizumab in patients with UC. To our knowledge, this is the first clinical study applying the CVAI index to reflect abdominal visceral adiposity in patients with UC. Further large-scale prospective studies are needed to confirm these findings.

Funding: This work was supported by the Department of Health of Zhejiang Province (2019RC302 to Yibing Hu), and the Science and Technology Plan Project of Jinhua Municipal Central Hospital (JY2020-6-06 to Yibing Hu).

Acknowledgments: We thank our patients and colleagues at Affiliated Jinhua Hospital, Zhejiang University School of Medicine.

Consent for publication: Not applicable. The study received an exemption from the Human Research Ethics Committee of Affiliated Jinhua Hospital, Zhejiang University School of Medicine and did not require informed consent. Verify that all methods are implemented in accordance with relevant guidelines and regulations.

Ethics approval and consent to participate: The study was approved by the Ethics Committee of Affiliated Jinhua Hospital, Zhejiang University School of Medicine (Approval No. 2024-29), and was performed in compliance to the Declaration of Helsinki.

REFERENCES

1. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. *Lancet* 2023;402:571-84. DOI: 10.1016/S0140-6736(23)00966-2
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017;390:2769-78. DOI: 10.1016/S0140-6736(17)32448-0

3. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. *Gastroenterology* 2013;145:158-65. e2. DOI: 10.1053/j.gastro.2013.04.007
4. Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. *JAMA* 2023;330:951-65. DOI: 10.1053/j.gastro.2013.04.007
5. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013;369:699-710. DOI: 10.1056/NEJMoa1215734
6. Gros B, Ross H, Nwabueze M, Constantine-Cooke N, Derikx L, Lyons M, et al. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis. *Therap Adv Gastroenterol* 2024;17:17562848241258372. DOI: 10.1177/17562848241258372
7. Karaskova E, Velganova-Veghova M, Geryk M, Foltanova H, Kucerova V, Karasek D. Role of Adipose Tissue in Inflammatory Bowel Disease. *Int J Mol Sci* 2021;22:4226. DOI: 10.3390/ijms22084226
8. Eder P, Adler M, Dobrowolska A, Kamhieh-Milz J, Witowski J. The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease. *Cells* 2019;8:628. DOI: 10.3390/cells8060628
9. Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. *Br J Radiol* 2016;89:20151024. DOI: 10.1259/bjr.20151024
10. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care* 2010;33:920-2. DOI: 10.2337/dc09-1825
11. Thomas DM, Bredlau C, Bony-Westphal A, Mueller M, Shen W, Gallagher D, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. *Obesity (Silver Spring)* 2013;21:2264-71. DOI: 10.1002/oby.20408
12. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. *PLoS One* 2012;7:e39504. DOI: 10.1371/journal.pone.0039504
13. Kahn HS. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. *BMC Cardiovasc Disord* 2005;5:26. DOI: 10.1186/1471-2261-5-26
14. Xia MF, Chen Y, Lin HD, Ma H, Li XM, Aleteng Q, et al. A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese. *Sci Rep* 2016;6:38214. DOI: 10.1038/srep38214
15. Tang M, Wei XH, Cao H, Zhen Q, Liu F, Wang YF, et al. Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus. *Front Endocrinol (Lausanne)* 2022;13:935980. DOI: 10.3389/fendo.2022.935980
16. Pan L, Xu Q, Liu J, Gao Y, Li J, Peng H, et al. Dose-response relationship between Chinese visceral adiposity index and type 2 diabetes mellitus among middle-aged and elderly Chinese. *Front Endocrinol (Lausanne)* 2022;13:959860. DOI: 10.3389/fendo.2022.959860
17. Tang N, Chen H, Chen R, Tang W, Zhang H. Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn's disease: a multicenter cohort study. *BMC Gastroenterol* 2022;22:229. DOI: 10.1186/s12876-022-02304-y
18. Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. *J Clin Med* 2021;10:4219. DOI: 10.3390/jcm10184219
19. Lee JW, Woo D, Kim KO, Kim ES, Kim SK, Lee HS, et al. Deep learning model using stool pictures for predicting endoscopic mucosal inflammation in patients with ulcerative colitis. *Am J Gastroenterol* 2025;120(1):213-24. DOI: 10.14309/ajg.0000000000002978
20. Swanson G, Behara R, Braun R, Keshavarzian A. Diagnostic medical radiation in inflammatory bowel disease: how to limit risk and maximize benefit. *Inflamm Bowel Dis* 2013;19:2501-8. DOI: 10.1097/MIB.0b013e31828dc6b6
21. Ślósarz D, Poniewierka E, Neubauer K, Kempirski R. Ultrasound Elastography in the Assessment of the Intestinal Changes in Inflammatory Bowel Disease-Systematic Review. *J Clin Med* 2021;10:4044. DOI: 10.3390/jcm10184044
22. Minordi LM, Bevere A, Papa A, Larosa L, Manfredi R. CT and MRI Evaluations in Crohn's Complications: A Guide for the Radiologist. *Acad Radiol* 2022;29:1206-27. DOI: 10.1016/j.acra.2021.07.025
23. Bojarski C, Waldner M, Rath T, Schürmann S, Neurath MF, Atraya R, et al. Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy. *Front Med (Lausanne)* 2021;8:655404. DOI: 10.3389/fmed.2021.655404
24. Nardo GD, Esposito G, Ziparo C, Micheli F, Masoni L, Villa MP, et al. Enteroscopy in children and adults with inflammatory bowel disease. *World J Gastroenterol* 2020;26:5944-58. DOI: 10.3748/wjg.v26.i39.5944
25. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2015;110:802-19; quiz 820. DOI: 10.1038/ajg.2015.120
26. Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, et al. Visceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. *Inflamm Bowel Dis* 2019;25:592-600. DOI: 10.1093/ibd/izy278
27. Thiberge C, Charpentier C, Gillibert A, Modzelewski R, Dacher JN, Savoye G, et al. Lower Subcutaneous or Visceral Adiposity Assessed by Abdominal Computed Tomography Could Predict Adverse Outcome in Patients With Crohn's Disease. *J Crohns Colitis* 2018;12:1429-37. DOI: 10.1093/ecco-jcc/jiy124
28. Yadav DP, Kedia S, Madhusudhan KS, Bopanna S, Goyal S, Jain S, et al. Body Composition in Crohn's Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration. *Can J Gastroenterol Hepatol* 2017;2017:1215035. DOI: 10.1155/2017/1215035
29. Sehgal P, Su S, Zech J, Nobel Y, Luk L, Economou I, et al. Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not. *Inflamm Bowel Dis* 2024;30:594-601. DOI: 10.1093/ibd/izad111
30. Li Y, Yu D, Yang Y, Cheng X, Piao W, Guo Q, et al. Comparison of Visceral Adiposity Indexes in Predicting Hypertension among Chinese Adults: Data from China Nutrition and Health Surveillance (2015-2017). *Nutrients* 2023;15:2146. DOI: 10.3390/nu15092146
31. Je Y, Han K, Chun J, Kim Y, Kim JH, Hoon Youn Y, et al. Association of Waist Circumference with the Risk of Inflammatory Bowel Disease: a Nationwide Cohort Study of 10 Million Individuals in Korea. *J Crohns Colitis* 2023;17:681-92. DOI: 10.1093/ecco-jcc/jjac193
32. Pasanta D, Htun KT, Pan J, Tungjai M, Kaewjaeng S, Chancharunee S, et al. Waist Circumference and BMI Are Strongly Correlated with MRI-Derived Fat Compartments in Young Adults. *Life (Basel)* 2021;11:643. DOI: 10.3390/life11070643
33. Yarur AJ, Bruss A, Moosreiner A, Beniwal-Patel P, Nunez L, Berens B, et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. *Gastroenterology* 2023;165:963-75.e5. DOI: 10.1053/j.gastro.2023.06.036
34. Morshedzadeh N, Shahrokh S, Aghdaei HA, Amin Pourhoseingholi M, Chaleshi V, Hekmatdoost A, et al. Effects of flaxseed and flaxseed oil supplement on serum levels of inflammatory markers, metabolic parameters and severity of disease in patients with ulcerative colitis. *Complement Ther Med* 2019;46:36-43. DOI: 10.1016/j.ctim.2019.07.012
35. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes Rev* 2002;3:141-6. DOI: 10.1046/j.1467-789x.2002.00065.x
36. Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. *Eur J Clin Nutr* 2010;64:2-5. DOI: 10.1038/ejcn.2009.139
37. Koutroumpakis E, Ramos-Rivers C, Regueiro M, Hashash JG, Barrie A, Swoger J, et al. Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. *Dig Dis Sci* 2016;61:865-71. DOI: 10.1007/s10620-015-3932-1
38. Huang K, Liu J, Xia W, Tian C, Yao L, Cao Q, et al. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China. *Front Pharmacol* 2023;14:1188751. DOI: 10.3389/fphar.2023.1188751
39. Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, et al. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. *Inflamm Bowel Dis* 2021;27:1931-41. DOI: 10.1093/ibd/izaa361
40. Gu P, Chhabra A, Chittajallu P, Chang C, Mendez D, Gilman A, et al. Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy. *Inflamm Bowel Dis* 2022;28:657-66. DOI: 10.1093/ibd/izaa361